In future studies, it will be important to identify tumour-specific KRAS-induced mechanisms, in order to specifically identify and stratify patients that might benefit from suppression of tumour-promoting inflammation or immunotherapies for the eventual success of KRAS-targeted therapies. The gene discussed is KRAS; the disease is neoplasm.